AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03672890 — intervention group
Intervention type: OTHER
Intervention: Telestroke
Description: Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening \& evaluation, and stroke education in patients admitted with stroke.
Study NCT03512938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal therapy
Description: Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
Study NCT03512938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
Study NCT02791763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 to 4 mg tablets of GSK1278863
Description: 7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
Study NCT02791763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg GSK1278863 tablet
Description: 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
Study NCT02791763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta pegol
Description: An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
Study NCT04341519 — intervention group
Intervention type: BEHAVIORAL
Intervention: PTSD
Description: family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
Study NCT04341519 — intervention group
Intervention type: BEHAVIORAL
Intervention: Burnout
Description: Symptoms of burnout as assessed by the Maslash Burnout Inventory
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study NCT00861952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuragen
Description: 2-3 drops applied topically 2-3 times per day as needed over a 3 month period
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Study NCT01867697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Study NCT00861952 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mineral oil
Description: Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
Study NCT01926288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Entecavir maleate tablets
Study NCT03736642 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: 12 ml sample
Study NCT01926288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: blank Baraclude tablets
Study NCT01926288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Blank maleate entecavir tablets
Study NCT01926288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baraclude tablets
Study NCT03736642 — intervention group
Intervention type: OTHER
Intervention: stool sampling
Description: 20 g sample
Study NCT03736642 — intervention group
Intervention type: OTHER
Intervention: urine sampling
Description: 18 ml sample
Study NCT03736642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests
Description: * Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale
Study NCT04383418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine nasal spray
Description: dexmedetomidine nasal spray
Study NCT04383418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine hydrochloride nasal spray blank preparation
Description: dexmedetomidine hydrochloride nasal spray blank preparation
Study NCT04492332 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard lumbar puncture
Description: Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
Study NCT04492332 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: standard lumbar puncture
Description: Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
Study NCT04522830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTL-TML-COVID
Description: Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Study NCT04522830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Study NCT01781299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm RTU
Study NCT01781299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SurgiMend PRS
Study NCT01099449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given IV
Study NCT01099449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Description: Given IV
Study NCT01099449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT01099449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given IV
Study NCT01099449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT01099449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin
Study NCT02267798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors.
Study NCT02267798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arm training combined with FES
Description: Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles.
Study NCT03803241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD133+ infusion
Description: Infusion of cells cd133+
Study NCT03803241 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: portal vein embolization
Description: portal vein embolization
Study NCT03803241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portal vein embolization
Description: portal vein embolization
Study NCT02448641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623 Implant (2.5M)
Description: 2.5 million SB623 cells
Study NCT02448641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623 Implant (5.0M)
Description: 5 million SB623 cells
Study NCT02448641 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery
Study NCT00770159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
Study NCT00770159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo to MK0822
Description: Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
Study NCT02174822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Study NCT02174822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Study NCT02174822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT01612806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix
Description: fetal bovine dermal scaffold
Study NCT01612806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PriMatrix Ag
Description: fetal bovine dermal scaffold with Ag
Study NCT01612806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moist wound therapy
Description: standard of care moist wound therapy
Study NCT01612806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: moist wound therapy
Description: standard of care moist wound therapy
Study NCT03156296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
Study NCT03156296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
Study NCT01286909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LaFlavon
Description: two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
Study NCT02464280 — intervention group
Intervention type: OTHER
Intervention: Tomosythesis scan of the lung or the wrist
Description: All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
Study NCT02464280 — intervention group
Intervention type: OTHER
Intervention: CT scan of the lung or the wrist
Description: All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
Study NCT02464280 — intervention group
Intervention type: OTHER
Intervention: conventional X-ray of the lung or the wrist
Description: All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
Study NCT03715647 — intervention group
Intervention type: OTHER
Intervention: Sepsis
Description: Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
Study NCT03715647 — intervention group
Intervention type: OTHER
Intervention: HELLP Syndrome
Description: Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
Study NCT04269798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Treatment
Description: conventional rehabilitation program for lower limb, balance and gait training
Study NCT04269798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment
Description: conventional rehabilitation program for lower limb, balance and gait training
Study NCT03715647 — intervention group
Intervention type: OTHER
Intervention: Respiratory Distress Syndrome Adult
Description: Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
Study NCT02375334 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical chart review by the Cancer Center ORIS and EPIC based systems
Study NCT03871218 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid group
Description: Applicaton of topical Hyaluronic acid
Study NCT01765218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
Study NCT01765218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo identical in appearance to the active agent (topiramate)
Study NCT04530136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruconest
Description: Patients will be randomized to Ruconest or Standard of Care
Study NCT04530136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ruconest
Description: Patients will be randomized to Ruconest or Standard of Care
Study NCT00648960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Single-dose 500 mg immediate-release oral tablet
Study NCT00648960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Single-dose 500 mg immediate-release oral dose
Study NCT03546452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: in vitro NGS-panel
Description: cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
Study NCT00791817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 200 mg capsule, single dose,fasted when dosed, duration is 4 days
Study NCT00791817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
Study NCT01475149 — intervention group
Intervention type: OTHER
Intervention: Phlebotomy
Description: Subjects will have blood drawn at each of the 3 study visits.
Study NCT02900716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRMWXHS-12
Description: DTRMWXHS-12
Study NCT02900716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRM-505
Description: DTRMWXHS-12 and everolimus
Study NCT02900716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRM-555
Description: DTRMWXHS-12 and everolimus and pomalidomide
Study NCT01911091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
Study NCT01691664 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Only radiation therapy
Description: Patients only radiation therapy after surgery
Study NCT01691664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus DC-CIK cellular therapy
Description: Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
Study NCT03453736 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a qualitative study involving staff interviews and observations. No intervention is being applied.
Study NCT01622322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
Study NCT01622322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
Study NCT04695561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Myofascial Relaxation
Description: Total of 12 times for 6 weeks
Study NCT04695561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Total of 12 times for 6 weeks
Study NCT04695561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only Exercise (Control)
Description: Every day for 6 weeks
Study NCT04055883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Description: All participants are administered one tablet per day for 96 weeks
Study NCT04055883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-1229
Description: All participants are administered one tablet per day for 96 weeks
Study NCT03368417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours.
Study NCT03368417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours.